Publications
Detailed Information
Implications of a splicing variant of AIMP2 lacking exon 2 among various cancer types including acute myelogenous leukemia : AIMP2-DX2 유전자의 2번 엑손 접합 변형이 급성 골수성 백혈병 및 기타 암종에서 가지는 임상적 의미
DC Field | Value | Language |
---|---|---|
dc.contributor.advisor | 윤성수 | - |
dc.contributor.author | 김률 | - |
dc.date.accessioned | 2017-07-19T10:37:45Z | - |
dc.date.available | 2017-07-19T10:37:45Z | - |
dc.date.issued | 2017-02 | - |
dc.identifier.other | 000000141925 | - |
dc.identifier.uri | https://hdl.handle.net/10371/132946 | - |
dc.description | 학위논문 (석사)-- 서울대학교 대학원 : 의학과, 2017. 2. 윤성수. | - |
dc.description.abstract | Aminoacyl tRNA synthetase complex-interacting multifunctional protein 2 (AIMP2) is a potent tumor suppressor. An exon-2 depleted splicing variant ofAIMP2 (AIMP2-DX2) is responsible for tumorigenesis by compromising the tumor suppressive activity of AIMP2. This study aimed to investigate the role ofAIMP2-DX2 over diverse cancers using whole transcriptome data in The Cancer Genome Atlas (TCGA), and International Cancer Genome Consortium (ICGC) database. A total of 753 samples were analyzed for the presence of AIMP2-DX2 and its prognostic role in various cancers. AIMP2-DX2 was universally expressed to varying degrees, with a prognostic implication in several cancers. In acute myemyeloid leukemia (AML), AIMP2-DX2/AIMP2 ratio was strongly correlated with major cancer signaling pathways, and had a tendency toward exhibiting poor prognosis (Log rank P=0.16). We validated the prognostic implication of AIMP2-DX2 using AML patient samples. For 51 AML patients, overall survival (OS) and progression-free survival (PFS) of AIMP2-DX2 positive patients were significantly
inferior to that of AIMP2-DX2 negative patients (for OS: hazard ratio [HR] 2.47 | - |
dc.description.abstract | 95% confidence interval [CI] 1.14–5.34 | - |
dc.description.abstract | P=0.022 | - |
dc.description.abstract | for PFS: HR 2.59 | - |
dc.description.abstract | 95% CI
1.32–5.11 | - |
dc.description.abstract | P=0.006). Collectively, AIMP2-DX2 may be a novel biomarker and a potential therapeutic target for AML. | - |
dc.description.tableofcontents | I. Introduction 1
II. Materials and Methods 3 III. Results 9 IV. Discussion 24 V. Conclusions 28 VI. References 29 Supplementary materials 34 Supplementary Figures 34 Supplementary Tables 51 국문 초록 54 | - |
dc.format | application/pdf | - |
dc.format.extent | 7052501 bytes | - |
dc.format.medium | application/pdf | - |
dc.language.iso | en | - |
dc.publisher | 서울대학교 대학원 | - |
dc.subject | AIMP2 lacking exon 2 | - |
dc.subject.ddc | 610 | - |
dc.title | Implications of a splicing variant of AIMP2 lacking exon 2 among various cancer types including acute myelogenous leukemia | - |
dc.title.alternative | AIMP2-DX2 유전자의 2번 엑손 접합 변형이 급성 골수성 백혈병 및 기타 암종에서 가지는 임상적 의미 | - |
dc.type | Thesis | - |
dc.description.degree | Master | - |
dc.citation.pages | 55 | - |
dc.contributor.affiliation | 의과대학 의학과 | - |
dc.date.awarded | 2017-02 | - |
- Appears in Collections:
- Files in This Item:
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.